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Background: Population-based self-reported data on off-label medicine use independent from health care
provisions are lacking. The purpose of this study is to investigate off-label medicine use in children and adolescents
in Germany in a non-clinical setting and to identify prevalence, determinants and spectrum of off-label
medicine use.
Methods: Data were obtained from the German Health Interview and Examination Survey for Children and
Adolescents (KiGGS) conducted by the Robert Koch Institute (2003–2006). 17,450 randomly selected children aged
0–17 years took part in the drug interviews. Of those, 8,899 took at least one medicine during the 7 days preceding
the interview. Off-label medicine use was defined as the discrepancy between actual use and the intended use
described in the summary of product characteristics. Off-label medicine use was stratified into off-label indication,
off-label age, off-label over-dosing, and off-label under-dosing.
Results: The prevalence rate of off-label medicine use among those who used medicines amount of is 40.2%. The
prevalence rate is significantly higher in boys (41.4%), in children aged 3 to 6 years (48.7%), without migration
background (40.9%), with high social status (42.5%), living in small (42.0%) and medium sized cities (41.6%), and
with a poor parents rated health status (41.7%). 12,667 preparations (attributable in respect to off-label use) were
taken by 8,899 children. 30% of the medicines have been used off-label. Off-label medicine use was highest in
preparations of the ATC-class “C00 Cardiovascular System”. In all origins of medicine, all age groups and all
ATC-classes under-dosing was the most frequent reason for off-label medicine use.
Conclusions: There is a considerable level of self-reported off-label medicines use in the general paediatric
population. Further investigations are needed to examine in how far off-label medicine use is based on lack of
knowledge or on empiricism in paediatric pharmacotherapy. Attention also needs to be paid to under-dosing
which potentially exposes drug users to risks of side effects without the benefit of a therapeutic effect. Clinical trials
for licensing of paediatric medicines, education of health care professionals, but also of parents and carers are
needed to ensure the rational use of medicines.
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Off-label medicine use among children and adolescents
constitutes an important public health issue as the ef-
fects and potential health risks may be unpredictable.
Pioneering work in this area was conducted already in
the year 1953 by the paediatrician F. Dost [1] who
stated, that children differ pharmacokinetically from
adults, and medication for adults cannot simply be ad-
ministered in smaller doses. As children differ in their
absorption, distribution, metabolism, and excretion of
medicine, they have special needs with respect to their
diseases and the dosing of medicines and they often re-
quire special formulations to permit administration of
adequate doses. Particularly young children are unable
to swallow tablets and are vulnerable to the taste of
medicine. However, many medicines are not specifically
developed for children. Among medicines which were
newly licensed by the European Medicine Agency
(EMA) between 1995 and 2005 only one third was spe-
cifically licensed for children [2]. There is hope that this
situation will improve with the Paediatric Regulation [3]
which came into force in 2007 and which requires com-
panies to develop a paediatric investigation plan (PIP),
while granting incentives once a license for paediatric
use has been obtained. Nevertheless, up to date there is
still a high use of off-label medicine in children. National
and international studies report a wide range of preva-
lence rates of off-label medicine use in children and ado-
lescents, reaching from 3.2% to 80% [4-18].
Studies reporting the extent of off-label medicine use
in the paediatric population are based on various data
sources, such as prescription-, health care insurance-, or
secondary care data. However, to our knowledge there
are no representative self-reported population based data
available. With the National Health Survey for Children
and Adolescents (KiGGS) [19] for the first time repre-
sentative self-reported data are available for analyzing
the exposition to off-label medicine use in the general
population of children and adolescents in Germany.
The present study utilizes population representative
epidemiological data of KiGGS to investigate off-label
medicine use in children and adolescents in a non-
clinical setting and independent from any health care
provisions. The objectives of this study are to assess the
prevalence rates, determinants and spectrum of off-label
medicine use. Furthermore, the spectrum of off-label
medicine use will be analyzed with respect to prescribing
status as well as in relation to the substance group.
Methods
Data collection and study population
Data for this study were collected within the German
Health Interview and Examination Survey for Children
and Adolescents (KiGGS) formally conducted by theRobert Koch Institute between May 2003 and May 2006.
The survey’s target population consisted of all non-
institutionalized children and adolescents aged between 0
and 17 years living in Germany. The design, sampling
strategy and study protocol have been described elsewhere
in detail [18]. Briefly, two-stage sampling procedures were
applied. In the first stage, a sample of 167 German munici-
palities (112 in the former West Germany, 55 in the
former East Germany) was drawn which was representa-
tive of municipality sizes and structures in Germany.
Stratified by sex and age, random samples of children and
adolescents between the ages of 0 and 17 years were then
drawn from local population registries in proportion to
the age and sex structure of Germany’s child population,
including children and adolescents with a foreign national-
ity. Children, who were at time of survey, in hospital or
medical nursing institutions were excluded. Among the
selected study participants the response rate was 66.6%. A
non-responder analysis was carried out to secure the rep-
resentativeness of the sample [19].
The final sample included 17,641 children and adoles-
cents (8,985 boys, 8,656 girls). All participants were invited
to the study centres and asked to take part in the following
data collection methods: to complete self-administered
questionnaires, to participate in computer-assisted struc-
tured interviews administered by physicians, to undergo
laboratory and other tests, and to take part in physical
medical examinations. Part of the physical medical exami-
nations was the documentation of standardized anthropo-
metric measures, of those, only the measurement of body
weight and height were relevant for this study. Other
relevant data for this study were collected via the self-
administered questionnaires (socio-economic status, mi-
gration background, parent-rated subjective health status
of their children), and the personal computer assisted in-
terviews administered by physicians (drug-use interview).
191 study participants did not take part in the drug-use
interview and were excluded, resulting in a basic popula-
tion of 17,450 (8,880 boys, 8,570 girls). Of those only par-
ticipants with at least one medicine usage (n = 8,899) were
included in our analyses of off-label medicine use.
The survey was approved by the Ethics Committee of
the Virchow Hospital, Humboldt University Berlin and
federal data-protection officials. Written, informed con-
sent was obtained prior to each interview and examin-
ation from the children’s parents and the children
themselves if they were aged ≥ 14 years.
Definition of health-related and socio-demographic
variables
While written, informed consent for participation in in-
terviews and examinations was obtained from all par-
ents/guardians as well as from children, aged ≥ 14 years,
children could already at the age of 11 years or older fill
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tionnaires were completed by the parents/guardians for
all children, also for adolescents who had completed the
standardised child questionnaire. These questionnaires
were used to collect e.g. information on socio-economic
data, family background, parent-rated child health status,
and health-related living conditions. A family socio-
economic status (SES) score was computed based on in-
formation obtained from both parents (if possible). The
SES-score included information on the educational level,
vocational status and the family net income [20]. After
computing a total score from the above mentioned items
with a minimum of 3 and a maximum of 21 points,
study participants were assigned to one of three status
groups depending on their individual score [20]. Partici-
pants were thus assigned to low, middle or high SES.
Family immigration status was assessed using infor-
mation on nationality, country of birth, and year of im-
migration of both parents. Study participants were
classified as having an immigration background if they
themselves were immigrants from another country and
at least one parent was not born in Germany, or if both
parents were immigrants or not of German nationality
[21]. Living in East or West Germany as well as living in
rural or urban areas was assessed by items concerning
the place of residence. Depending on the number of
inhabitants, communities were distinguished as rural
(< 5,000), small-sized urban (5,000 - < 20,000), medium-
sized urban (20,000 - < 100,000), and large city (100,000
and more). Parents rated the general health status of
their children as ‘’excellent’, ‘good’, ‘moderate’, ‘bad’ or
‘very bad’. Because of the small numbers, within the last
three categories they were summarised as ‘moderate/
bad/very bad’.
Assessment of medicine use
The use of any medication in the last seven days, including
prescribed and OTC drugs was assessed in a face-to-face
interview. The interviews were conducted by physicians
using a standardized computer-assisted personal drug use
interview tool [22]. All survey participants and parents
were asked in advance to bring prescriptions or original
packages to the examination site to facilitate the investiga-
tion and verification of drug use. Drug use was assessed by
the following question:
‘Has your child taken any drugs in the last seven
days? Please also mention the use of any ointments,
liniments, contraceptive pills, vitamin and mineral
supplements, medicinal teas, herbal or homoeopathic
medicines’.
Details on every drug mentioned were collected
such as brand name, indication, daily dose, route ofapplication, frequency of intake, origin of the drug
and duration of use.
Specific Anatomical Therapeutic Chemical codes (ATC-
codes) were assigned to all reported medications, and
International Classification of Diseases-10. Revision codes
(WHO ICD-10 codes) to the conditions for which the
medications were taken.
Off-label medicine use was stratified by self-medicated
and prescribed preparations. Self-medicated preparations
were defined as medicines that were either bought OTC
or obtained from other sources. Prescribed medicines
were preparations that were prescribed by a physician or
by a non-medical practitioner.Data processing
Based on information provided by the study participants
about the usage of each medicine (brand name, indica-
tion, dose, and frequency of use) and on characteristics
of the study participants (age, height, body weight) a
comparison was made with the summary of product
characteristics (SPC) or patient information leaflet. If
this comparison showed a discrepancy between actual
and licensed usage the utilization was considered as off-
label medicine use. Off-label medicine use was classified







Off-label indication was defined as the discrepancy be-
tween self-reported indication and the indication of the
SPC. The same applies to the other chosen categories
(off-label age, off-label over-dosing, off-label under-dosing).
No off-label medicine use (in-label) was assigned if self-
reported and SPC information was identical. If the avail-
able data about the medicine used was imprecise, the
preparation was classified as not-attributable. Each prod-
uct could only be classified in one category. If the product
was off-label in more than one category off-label indica-
tion had highest priority followed by age, over-dosing, and
under-dosing, respectively.
SPC and patient information leaflet were primarily
taken from the German drug dictionary “Gelbe Liste”
[23]. If this information was insufficient, “Rote Liste”
[24], a different German drug dictionary, was con-
sulted alternatively. If the information was still insuffi-
cient an internet research was conducted and if this
was also unsuccessful the product was classified as
“not-attributable”.
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girls who took at least one off-label preparation. Chil-
dren with in-label medicine use were defined as the total
number of children and adolescent who took all their
medicines in-label. Boys and girls exclusively using prep-
arations that could not be allocated were defined as chil-
dren with not-attributable off-label medicine use.
Quality control
To determine the accuracy of the off-label assessment a
5% random sample (n = 738) was re-assessed by an ex-
ternal reviewer with previous experience in off-label
medicine use in children. Interrater reliability between
the original assessment and the second reviewer for the
random sample was calculated using Kappa Statistics.
Statistical analysis
In order to achieve a representativeness of the survey
population a weighting factor was computed and used to
adjust for deviations in demographic characteristics. This
was a necessary step as the sampling was based on a two
stage procedure (see chapter “Methods”, sub-chapter
“Data collection and study population”). Basis for the ad-
justments was a comparison of the survey population
with the official population statistics.
Descriptive statistics (proportions and 95% confidence
intervals) were calculated to estimate prevalence rates of
overall drug use, in-label- and off-label medicine use
according to sex, age, region of residence, urbanity, mi-
gration background, social status, and parents’ rated
health status.
In a multivariate logistic regression model odds ratios
(ORs) and 95% confidence intervals (95% CIs) were
estimated. The dependent variable was off-label versus
in-label medicine use. In the logistic regression model
children exclusively using not-attributable preparations
were excluded. All variables of the descriptive calcula-
tion were included in the model as potentially determin-
ing factors.
Group differences were considered statistically signifi-
cant if the 95% CIs of two rates did not overlap or the
p-values were ≤ 0.05. All statistical analyses were per-
formed using SPSS statistical software (release 20.0). In
order to adjust for sample clustering effects, the SPSS
complex samples module was used for all analyses.
Results
Prevalence and determinants of off-label use
A total of 17,450 children and adolescents participated
in the drug interview. 8,899 boys and girls use at least
one medication in the last seven days and thus consti-
tute our study population.
Prevalence of medicine use is shown in Table 1. Girls
have a significantly higher prevalence rate of drug usethan boys. With increasing age the prevalence of medicine
use is decreasing. Until the age of 2 years the medicine use
is significantly higher than in all other age groups. There
are no differences according to region of residence or
according to urbanity. Children with a migration back-
ground or from families with a lower social status are sig-
nificantly less often medicine user. Looking at the parents’
rated health status we find that children with a better
health status use significantly less medication.
Among the study subjects 3,610 (40.2% 95% CI 38.8-
41.5%) boys and girls use one or more preparations
off-label. 4,334 children and adolescents use all their
preparations exclusively in-label (48.7% 95% CI 47.3-
50.2%). For 11.1% (95% CI 10.3-12.0%) of children with
drug use (n = 955), it was not possible to identify in- or
off-label use for any of their medications (Figure 1).
Regarding off-label medicine use statistically significant
differences can be observed with respect to sex and age.
Boys have a higher prevalence rate than girls (41.4 vs.
38.9%). Those below 2 years of age and those 14 years of
age or older use significantly less off-label medication
compared to those aged between 3 and 13 years. There
are no significant differences according to region of resi-
dence and urbanity. Children and adolescents from fam-
ilies without migration background and from families with
higher social status have a higher off-label medicine use,
but the differences are only significant for migration back-
ground. Boys and girls whose parents indicated an excel-
lent health status of their children receive significantly less
off-label medication compared to those with a moderate/
bad/very bad health status (Table 1).
The prevalence rate of children exclusively using in-label
medicines, amounts to 48.7%. Exclusive in-label medicine
use is significantly higher e.g. in girls, in the age groups 0
to 2 and 14 to 17 years, and in rural areas. Children with
an excellent parents’ rated health status use their medica-
tion also more often exclusively in-label (Table 1).
For 955 participants (11.1%) the reported medicines
could not be allocated with respect to in- or off-label
medicine use, because information regarding the prepa-
rations was unspecific. Those children are significantly
more often boys than girls (12.4 vs. 9.8%), and less often
aged 0 to 2 years. Children with migration background
or living in families with a lower social status have a sig-
nificantly higher rate of not-attributable medicine use.
There are no significant differences in the prevalence
rate of not-attributable medicine use according to par-
ents’ rated health status (Table 1).
In the logistic regression model sex, age, urbanity and
parents’ rated health status are independent determining
factors for the probability of off-label medicine use. Boys
have a significantly higher OR than girls, and children
up to 13 years of age have a higher OR than adolescents
(14 to 17 years). Living in rural areas is associated with a
Table 1 Prevalence and determinants of off-label medicine use, KiGGS 2003-2006
Children with drug





















n % 95% CI % 95% CI % 95% CI % 95% CI OR 95% CI p-value
Total 8,899 50.8 (49.5-52.2) 40.2 (38.8-41.5) 48.7 (47.3-50.2) 11.1 (10.3-12.0)
Sex .015
Boys 4,362 48.7 (47.2-50.3) 41.4 (39.7-43.1) 46.2 (44.5-47.9) 12.4 (11.3-13.6) 1.13 (1.03-1.25)
Girls 4,537 53.1 (51.5-54.7) 38.9 (37.1-38.8) 51.2 (49.3-53.2) 9.8 (8.9-10.9) 1(Referenz)
Age group < .001
0 - 2 years 2,089 74.9 (72.9-76.9) 42.4 (39.8-45.1) 53.1 (50.3-55.9) 4.5 (3.5-5.8) 1.45 (1.24-1.69)
3 - 6 years 1,939 51.1 (48.8-53.3) 48.7 (46.1-51.4) 39.7 (37.2-42.2) 11.6 (10.0-13.4) 2.08 (1.79-2.41)
7 - 10 years 1,718 42.6 (40.4-44.8) 41.3 (38.9-43.8) 45.7 (43.3-48.1) 13.0 (11.4-14.8) 1.52 1.31-1.78)
11 - 13 years 1,289 42.4 (40.1-44.7) 36.9 (34.0-40.0) 46.5 (43.1-49.8) 16.6 (14.3-19.2) 1.36 (1.15-1.60)
14 - 17 years 1,864 50.7 (49.5-52.2) 32.5 (30.2-34.8) 56.1 (53.6-58.8) 11.4 (9.9-13.1) 1(Referenz)
Region .355
East 2,881 51.7 (49.2-54.2) 40.3 (38.3-42.4) 50.1 (47.9-52.2) 9.6 (8.7-10.7) 1.06 (0.93-1-19)
West 6,018 50.7 (49.2-52.2) 40.1 (38.5-41.7) 48.5 (46.8-50.2) 11.4 (10.5-12.4) 1(Referenz)
Urbanity .022
Rural area 1,985 50.5 (47.8-53.1) 36.5 (33.4-39.8) 54.5 (51.0-58.0) 8.9 (7.1-11.1) 0.83 (0.69-1.00)
Small city 2,314 50.9 (48.3-53.5) 42.0 (39.0-45.0) 47.3 (44.6-49.6) 10.8 (9.3-12.4) 1.10 (0.92-1.30)
Medium-sized city 2,561 50.7 (48.2-53.3) 41.6 (39.4-43.8) 47.3 (45.2-49.4) 11.1 (10.0-12.4) 1.07 (0.91-1.24)
Large city 2,039 51.2 (48.4-53.9) 39.1 (36.8-41.5) 47.9 (45.1-50.8) 12.9 (11.2-14.9) 1(Referenz)
Migrant background .954
Yes 1,071 41.4 (38.8-44.2) 35.8 (32.6-39.1) 44.1 (40.5-47.8) 20.1 (17.5-22.9) 0.99 (0.82-1.21)
No 7,788 52.8 (51.5-54.1) 40.9 (39.4-42.3) 49.5 (48.0-51.1) 9.6 (8.8-10.4) 1(Referenz)
Missing 40
Social status .157
Low 2,249 47.1 (45.0-49.2) 39.1 (36.6-41.7) 47.0 (44.4-49.7) 13.9 (12.1-15.8) 0.91 (0.78-1.07)
Middle 4,083 51.2 (49.7-52.7) 39.9 (37.9-41.9) 50.4 (48.3-52.5) 9.7 (8.6-10.8) 0.90 (0.80-1.00)
High 2,403 55.1 (53.0-57.3) 42.5 (40.4-44.7) 47.6 (45.4-49.8) 9.9 (8.5-11.4) 1(Referenz)
Missing 164
Parents’ rated subjective health status < .001
Excellent 3,261 47.2 (45.4-48.9) 38.2 (36.1-40.3) 51.7 (49.6-53.8) 10.1 (9.1-11.2) 0.71 (0.58-0.88)
Good 4,840 52.1 (50.6-62.9) 41.2 (39.4-42.9) 47.1 (45.3-49.0) 11.7 (10.5-13.0) 0.89 (0.73-1.07)
Moderate/Bad/Very Bad 798 60.0 (49.5-52.2) 41.7 (37.9-45.6) 46.7 (42.8-50.7) 11.6 (9.3-14.3) 1(Referenz)
n unweighted, % weighted.
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If the parents rated the health status of their children as
excellent the OR is significantly lower compared to a
moderate/bad/very bad health status (Table 1).
Spectrum of off-label use
8,899 study participants had taken 14,588 preparations
resulting in an average of 1.62 (95% CI 1.59-1.66) prep-
aration per drug user.Among 14,588 preparations recorded, 3,802 are classi-
fied as “off-label”, 8,865 as “in-label” and 1,921 (13.2%)
as “not-attributable”. After excluding not-attributable
preparations there are 12,667 preparations left for fur-
ther analyses. Among these 12,667 medicines 70.0% are
used in-label. Within the remaining 30% off-label use,
under-dosing (17.4%) is the most frequent category,
followed by over-dosing (4.6%), indication (4.3%), and
age (3.8%) (Figure 2).
Figure 1 Prevalence of children with off-label-, in-label-,
and not-attributable medicine use, KiGGS 2003–2006.
Figure 3 Off-label medicine use by off-label strata and age
groups, KiGGS 2003–2006.
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according to age groups is illustrated. In all age groups
under-dosing is the main reason for off-label use (0–2 years
11.8%, 3–6 years 22.6%, 7–10 years 21.5%, 11–13 years
18.7%, and 14–17 years 15.0%). Age is the second most
common reason for off-label medicine use in the age group
0–2 years (6.2%) and over-dosing in the age group 3 –
6 years (6.9%). Indication is the second most common rea-
son in all other age groups (7–10 years: 4.4%, 11–13 years:
4.6%, and 14–17 years: 5.5%).
61.2% of the used preparations are prescribed by a
physician or a non-medical practioner, 38.8% are self-
medicated (OTC 24.7%, 14.1% from other sources).
Looking at off-label medicine use according to origins of
medicines (prescribed, OTC, other sources) we find the
following results: about 30% of prescribed as well as OTC
products or preparations from other sources are used off-
label. Under-dosing is the most common off-label use in
all categories (prescribed medicines: 16.1%, OTC: 19.3%,
medicines from other sources: 20.2%). Under-dosing is
significantly more frequent in OTC products and prepara-
tions from other sources compared to prescribed medi-
cines. In contrast, off-label indication is significantly
higher in prescribed medication than in OTC products
and preparations from other sources (Table 2).Figure 2 Drug use by in-label and off-label medicine use (only attribuIn our study we also analyzed off-label medicine use
according to ATC-classes/ATC-substance-groups. Overall
off-label medicine use is highest (67.2%) for products be-
longing to the cardiovascular system (ATC-code C00) and
lowest (13.3%) for products belonging to urogenital tract
and sexual hormones (ATC-code G00). Off-label age and
off-label indication is higher in the ATC- class C00 and
in the ATC-class L00 (antineoplastic and immune
modulating agents). In all other ATC-classes off-label
under-dosing is dominating. This includes e.g. antibiotics
(ATC-code J01) with 21.3% under-dosing (Table 3).
Off-label medicine use stratified by ATC-classes shows
differences in the various age groups. Until the age of
2 years the most frequently used preparations are medica-
tions for sensory organs (ATC-code S00), followed by
medicines for the respiratory system (ATC-code R00) and
for antiinfectives for systemic use (ATC-code J00). In the
age of 3 to 10 years preparations for alimentary tract and
metabolism (ATC-code A00), for sensory organs (ATC-
code S00) and for respiratory system (ATC-code R00)
dominate off-label medicine use. In adolescents and
youths (11 to 17 years) most often used off-label medi-
cines are preparations of the ATC-class A00 (alimentarytable preparations), KiGGS 2003–2006.
Table 2 Off-label and in-label medicine use by origin of medicines, KiGGS 2003-2006
Drug use categories Origin of medicines (n = 12,587*)
Prescribed OTC Other sources
n % 95% CI n % 95% CI n % 95% CI
Off-label medicine use 2,344 29.9 (28.9-30.9) 925 30.3 (28.7-31.9) 515 30.6 (28.5-32.9)
➢ Indication 376 4.8 (4.3-5.2) 106 3.5 (2.9-4.2) 56 3.3 (2.6-4.3)
➢ Age 326 4.2 (3.7-4.6) 100 3.3 (2.7-4.0) 45 2.7 (2.0-3.6)
➢ Under-dosing 1,263 16.1 (15.3-16.9) 590 19.3 (18.0-20.8) 339 20.2 (18.3-22.2)
➢ Over-dosing 379 4.8 (4.4-5.3) 129 4.2 (3.6-5.0) 75 4.5 (3.6-5.6)
In-label medicine use 5,508 70.1 (69.1-71.1) 2,129 69.7 (68.1-71.3) 1,166 69.4 (67.1-71.5)
* Discrepancy to total n = 12,667 because of missing data (n = 80). OTC = Over the Counter.
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tologicals) and S00 (sensory organs) (Table 4).
Quality control
The re-assessment of a 5% random-sample by a second
reviewer revealed a similar distribution for off-label
medicine use. Inter-rater reliability was found to be
“good” (Kappa = 0.655).
Discussion
Principle findings
Looking at the population level, the prevalence rate of off-
label medicine use in children/adolescents, who took at
least one preparation amounts to 40.2%. Off-label medi-
cine use is statistically significantly higher in boys and
lower in adolescents (14–17 years). There are no signifi-
cant differences according to region, urbanity, migrant
background, and social class. A better parents-rated health
status of their children is associated with a lower probabil-
ity of off-label medicine use. Looking at the preparation
level, 70% of all attributable preparations are used in-label
and 30% off-label. The spectrum of off-label medicine use
is dominated by under-dosing (17.4%), followed by over-
dosing (4.6%), indication (4.3%), and age (3.8%). Further-
more we found that under-dosing is the most common
reason for off-label-use in prescribed medicines as well as
in self-medication.
Strengths and limitations
The KiGGS study provides representative population-
based data on drug use among children and adolescents.
The data have been obtained by physicians administered
structured interviews including a population of more
than 17,000 children and adolescents. Data obtained in
this study are independent from the provision of health
care and provide information about the “real” use of
medicines in the population. In contrast, studies utiliz-
ing prescription data, health insurance data, secondary
care data, or medication sales data are unable to
consider if patients actually took the medicines and thus
do not represent the real use. Prescribed or OTCmedication may be taken in various quantities, at a dif-
ferent point of time or by a different person. In this
study, information on drug use was obtained by face-to-
face interviews, which contributes to reliable data on
actual use of medication.
The findings of this study are generalizable with re-
spect to off-label use of medicine among children and
adolescents aged 0–17 years in Germany. Whereas the
analysis of prescription data only allows conclusions
about off-label prescription but not about off-label
medicine use, and the data on sales of OTC medicine
does not give information on user patterns, the KiGGS-
data provide information about the use and off-label
use of all medications including OTC products and
medicines from other sources. In addition KiGGS pro-
vides information on the associations between socio-
economic as well as health-relevant indicators and
off-label medicine use. Thus the results of our study
are unique in Germany and international.
However, this study also has several limitations. Infor-
mation regarding the use of medication collected were
provided by parents and/or supplemented with informa-
tion from the adolescents. Therefore a recall-bias has to
be considered. In order to minimise this effect parents
and children/adolescents were asked to bring along
packages from all products recently used. But only for
about 30% of recorded preparations this was done. Even
though this proportion is low, about 87% of all prepara-
tions could be assessed according to off-label use. This
underlines that the information relying on memorising
preparations used in the last seven days are of a suffi-
cient validity.
Memory problems are mainly related to dosing infor-
mation, particularly if the product is not used regularly.
The high proportion of under-dosing may indicate this
problem, however, previous studies evaluating off-label
medicine use and considering the dosing came to similar
results as our study [11,12].
Another limitation can arise from the self-reported rea-
son for treatment (indication). This may be inadequate as
there may be problems regarding the communication
Table 3 Off-label and in-label medicine use by ATC-classes and off-label strata, KiGGS 2003-2006







n % n % n % n % n % n
Total 541 4.3 476 3.8% 583 4.6 2,202 17.4 8,865 70.0 12,667
A00 ALIMENTARY TRACT and METABOLISM 140 4.8 113 3.9% 86 2.9 654 22.4 1,933 66.1 2,926
A01 Stomatological preparations 47 2.8 80 4.7% 41 2.4 308 18.2 1215 71.9 1691
A03 Antispasmodic and anticholinergic agents and propulsives 6 4.7 3 2.4 8 6.3 18 14.2 92 72.4 127
A07 Antidiarrheals. Intestinal Antiinflammatory/Antiinfektive Agents 5 4.9 7 6.8 6 5.8 11 10.7 74 71.8 103
A11 Vitamins 35 5.1 10 1.4 18 2.6 218 31.5 411 59.4 692
A12 Mineral Supplements 42 22.5 4 2.1 6 3.2 84 44.9 51 27.3 187
A14 Anabolic Agents for Systemic Use 0 0 0 0 0 0 0 0 2 100 2
B00 BLOOD and BLOOD FORMING ORGANS 0 0 4 5.5 3 4.1 17 23.3 49 67.1 73
C00 CARDIOVASKULAR SYSTEM 3 5.2 11 19.0 3 5.2 22 37.9 19 32.8 58
C01 Cardic Therapy 0 0 0 0 0 0 3 30.0 7 70.0 10
C05 Vasoprotectives 1 4.0 0 0 1 4.0 17 68.0 6 24.0 25
C07 Beta Blocking Agents 1 10.0 7 70.0 0 0 1 10.0 1 10.0 10
D00 DERMATOLOGICALS 69 4.4 42 2.7 30 1.9 344 21.8 1,094 69.3 1579
D01 Antifungals for Dermatological Use 7 6.1 1 0.9 5 4.3 21 18.3 81 70.4 115
D02 Emollients and Protectives 4 1.6 4 1.6 4 1.6 29 11.9 203 83.2 244
D03 Preparations for Treatment of Wounds and Ulcers 17 5.3 2 0.6 0 0 3 0.9 297 93.1 319
D04 Antipruritics. incl. Antihistamines. Anesthetics etc. 1 0.6 1 0.6 1 0.6 46 28.6 112 69.6 161
D06 Antibiotics and Chemotherapeutics for Dermatological Use 10 11.6 1 1.2 2 2.3 49 57.0 24 27.9 86
D07 Corticosteroids. Dermatological Preparations 23 10.2 15 6.6 13 5.8 95 42.0 80 35.4 226
D10 Anti-Akne Preparations 2 1.8 0 0 1 0.9 28 25.5 79 71.8 110
D11 Other Dermatological Preparations 4 1.8 16 7.4 3 1.4 69 31.8 125 57.6 217
G00 GENITO URINARY SYSTEM and SEX HORMONES 52 10.5 2 0.4 4 0.8 8 1.6 431 86.7 497
G03 Sex Hormones and Modulators of the Genital System 48 10.6 1 0.2 3 0.7 2 0.4 398 88.1 452
H00 SYSTEMIC HORMONAL PREPARATIONS. excl. SEX HORMONES
and INSULINS
6 2.0 0 0 7 2.4 29 9.8 253 85.8 2,,95
H03 Thyroid Therapy 1 0.4 0 0 5 2.0 28 11.4 212 86.2 246
J00 ANTIINFECTIVES for SYSTEMIC USE 25 6.7 5 1.3 21 5.6 71 19.0 252 67.4 374
J01 Antibiotics for Systemic Use 25 7.5 4 1.2 21 6.3 71 21.3 212 63.7 333
L00 ANTINEOPLASTIC and IMMUNMODULATING AGENTS 8 9.4 7 8.2 5 5.9 24 28.2 41 48.2 85
L03 Immunostimulants 8 11.3 6 8.5 4 5.6 23 32.4 30 42.3 71
M00 MUSCULO-SKELETAL SYSTEM 11 2.0 31 5.6 8 1.5 47 8.5 454 82.4 551
M01 Antiinflammatory and Antirheumatic Products 2 0.8 16 6.4 6 2.4 26 10.4 200 80.0 250
M02 Topical Products for Joint and Muscular Pain 7 2.5 14 5.0 1 0.4 16 5.7 242 86.4 280
N00 NERVOUS SYSTEM 28 2.6 43 3.9 11 1.0 93 8.5 921 84.0 1,096
N02 Analgesics 11 1.4 30 3.9 5 0.6 66 8.5 664 85.6 776
N06 Psychoanaleptics 7 3.8 2 1.1 0 0.0 9 4.9 167 90.3 185
R00 RESPIRATORY SYSTEM 94 2.4 202 5.2 334 8.6 786 20.2 2477 63.6 3,893
R01 Nasal Preparations 13 1.3 55 5.5 18 1.8 60 6.1 845 85.3 991
R02 Throat Preparations 2 1.3 2 1.3 13 8.7 9 6.0 124 82.7 150
R03 Anti-Asthmatics 20 3.5 46 8.0 16 2.8 72 12.6 419 73.1 573
R04 Chest Ointments. Inhalatives 3 1.0 35 11.3 0 0.0 108 34.7 165 53.1 311
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Table 3 Off-label and in-label medicine use by ATC-classes and off-label strata, KiGGS 2003-2006 (Continued)
R05 Cough and Cold Preparations 42 2.6 54 3.3 278 16.9 476 28.9 797 48.4 1647
R06 Antihistamines for Systemic Use 13 6.1 10 4.7 9 4.2 60 28.3 120 56.6 212
S00 SENSORY ORGANS 20 10.0 2 1.0 10 5.0 60 30.0 108 54.0 200
S01 Ophthalmologicals 19 13.4 2 1.4 2 1.4 47 33.1 72 50.7 142
S02 Otologicals 1 1.9 0 0 7 13.5 11 21.2 33 63.5 52
V00 VARIOUS 5 2.3 1 0.5 6 2.8 23 10.6 183 83.9 218
V03 All Other Therapeutic Products 3 3.0 0 0 4 4.0 18 18.2 74 74.7 99
V06 General Nutrients 0 0 1 2.0 2 4.0 5 10.0 42 84.0 50
Z00 HOMOEOPATHICS 80 10.0 11 1.4 55 6.9 23 2.9 631 78.9 800
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leading to a misunderstanding of the indication. Our re-
sults support this assumption, as they show that chil-
dren with migration background or from families with a
lower social status have a significantly higher prevalence
rate of exclusively not-attributable medicine use.
Prevalence and determinants of off-label medicine use
Population representative data regarding off-label medi-
cine use in children and adolescents which are inde-
pendent from any health care provisions are rare in
the literature. The prevalence of off-label use among
medicine users identified in our study is 40.2%. This
differs from the results of a Scottish study (Ekins-
Daukes et al.) where prevalence is found to be 10.6%
[11]. Cuzzolin et al. reviewed international studies and
report unlicensed and off-label rates in ambulatory
care between 13.2% and 29%, in paediatric wardsTable 4 Off-label medicine use by ATC-classes and age group
ATC-class
A00 Alimentary tract and metabolism
B00 Blood and blood forming organs
C00 Cardiovascular system
D00 Dermatologicals
G00 Genito urinary system and sex hormones
H00 Systemic hormon. preparations excl. sex hormones and insulins
J00 Antiinfectives for systemic use
L00 Antineoplastic and immunmodulating agents
M00 Musculo-skeletal system
N00 Nervous system





TOTAL n = 12,667between 18% and 60% and in neonatal units between
14% and 63% [12]. Another international literature re-
view by Pandolfini and Bonati reports that rates for
off-label medicine use vary between 11% and 80%.
Higher rates are seen in younger patients and in hos-
pital settings [17]. However, comparing these studies
with our data is difficult as there are differences in re-
spect to the study design, study population and periods
of observation.
In our analysis children who were aged 3 to 13 years
show higher off-label medicine use compared to those
drug users aged 0–2 years and 14–17 years respectively.
This is contradictory to the findings of previously pub-
lished studies where highest rates for off-label medicine
use are in neonates [4,11,18,25-27]. The main reason for
these differences may be related to differences in the
study population. While the KIGGS study population in-
cludes no hospitalized and mainly healthy children,s, KiGGS 2003-2006
0-2 years 3-6 years 7-10 years 11-13 years 14-17 years
n (%) n (%) n (%) n (%) n (%)
328 (21.3) 255 (49.5) 172 (50.0) 108 (47.8) 130 (43.0)
2 (13.3) 1 (14.3) 2 (50.0) 10 (52.6) 9 (32.1)
3 (100) 2 (40.0) 9 (64.3) 9 (90.0) 16 (61.5)
102 (26.6) 106 (30.1) 110 (31.0) 75 (37.1) 92 (32.1)
4 (66.7) 1 (10.0) 6 (50.0) 2 (25.0) 53 (11.5)
3 (14.3) 11 (19.3) 7 (13.7) 7 (9.5) 14 (15.2)
29 (32.2) 41 (36.6) 18 (30.5) 15 (31.9) 19 (28.8)
7 (70.0) 16 (57.1) 8 (42.1) 6 (42.9) 7 (50.0)
13 (25.5) 17 (23.3) 18 (16.8) 21 (18.9) 28 (13.4)
20 (12.7) 21 (20.2) 51 (25.5) 39 (16.5) 44 (11.1)
1 (33.3) 1 (20.0) 1 (14.3) 0
356 (39.1) 493 (40.4) 288 (35.7) 146 (30.7) 133 (27.7)
30 (56.6) 30 (42.3) 13 (61.9) 11 (36.7) 8 (32.0)
16 (16.3) 6 (25.0) 7 (16.7) 1 (5.6) 5 (13.9)
41 (23.2) 47 (20.3) 37 (19.2) 22 (20.6) 22 (23.9)
954 (27.1) 1048 (37.3) 747 (33.5) 473 (29.8) 580 (23.0)
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tensive care patients.
Spectrum of off-label medicine use
In our study 30% of all attributable products are used
off-label. This proportion is above the previously
reported data (13.2%) in Germany (Buecheler et al.).
However, Buecheler et al. do not supply information re-
garding dosing and indication [4]. Consequently their
data are underestimating the prevalence which may ex-
plain the difference to our findings. T’Jong et al. report
in their study from the Netherlands that 44% of all pre-
scriptions in a paediatric ward are off-label [28]. In am-
bulant patients this rate amounts to 23% and is slightly
lower compared to the findings in our study [29].
Under-dosing is the most frequent reason for off-label
medicine use in our study, accounting for more than half
of all off-label medications. Similar findings were previ-
ously reported from Scotland and Brazil [11,30].
Off-label medicine use such as under- and over-dosing
could bear the risk of potential health hazards. Inappro-
priate dosing is of particular concern for antibiotic use
with respect to the development of resistances [31,32]
but also regarding adverse drug reactions (ADRs)
[33-35]. If medication is under-dosed possibly no thera-
peutic benefit but a risk for ADRs could occur, as those
often are independent of the dose. In our study 36% of
antibiotics are used off-label, of those 58% are under-
dosed. Similar findings are reported from Porta et al.
who found that under-dosing of antibiotics is the most
common reason for off-label use in the UK and in Italy
[30]. A Scottish study of Ekins-Daukes et al. reports that
the number of children who had been prescribed antibi-
otics of a less than recommended dose increases with
age from 11.8% in the age group 0–4 years to 30.0% in
the age group 12–16 years [36]. The problem is also
highlighted in a historic review from England by Ahmed
et al. who is concerned that many antibiotics used in
children are under-dosed [37].
Menson et al. investigate the use of anti-retrovirals in
UK and Irish children and identify that children have
frequently been under-dosed with anti-retrovirals over
the observed 9 year period [38]. Major reasons identified
are inconsistent dosage strategies or failure to respond
to growth, especially at extremes of weight bands. As
children grow, drug doses need regular adjustment and
failure to do so may reduce the benefits of treatment.
Kazouini et al. analyse Paracetamol prescription issued
in 2006 to Scottish children and find that 13.3% of pre-
scriptions are under-dosed and 4.4% are over-dosed [39].
In a similar study the authors show that prescribing of
antibiotics below the recommended doses is more fre-
quent than the prescribing of doses which are above offi-
cial recommendations [36]. This implies that the overalllarge extent of under-dosing regarding the use of drugs
in children is not exclusive to Germany. However, most
of the previously published data come from hospital or
ambulatory care settings.
In our setting which was independent from health care
provisions there is a large amount of self-medication
(38.8%). This is not surprising and has previously already
been reported in a study by Du and Knopf [40]. In the
present study, within self-medication, off-label medicine
use amounts to about 30% (OTC 30.3%, other sources
30.6%). Our data are representative for Germany and we
could not identify any published studies from other
countries related to off-label medicine use of self-
medication, including OTC products. In self-medication
as well as in prescribed medicine under-dosing is the
most frequent reason for off-label medicine use, but in
self-medication under-dosing is significantly higher.
Here further studies are needed to investigate the rea-
sons why there is such a high level of under-dosing of
children’s medication. From a pharmacological point of
view this doesn’t make sense because adverse reactions
can occur at any dose whereas the desired effect is
always related to the therapeutic dose. Furthermore, al-
though the relationship is not significant in our analysis,
the fact that children without migration background and
with higher social status take more off-label medicine
throws up the question why these groups of children are
more likely to be exposed to off-label medicine use. A
relationship between socio-economic factors and self-
medication use was reported previously from various
countries [40-43]. A study of Du and Knopf shows that
parents with higher social economic status tend to
utilize more self-medication for their children [40].Conclusions
Our data show that there is a high level of off-label
medicine use in the general paediatric population and
that under-dosing is the most frequent reason for off-
label use. This could put drug users at the risk of side
effects without a therapeutic effect. Particularly for anti-
biotics the development of resistances is fostered when
too low doses are given.
With respect to rational use of medicines the correct
dose should be given to ensure safety and effectiveness
of pharmacotherapy. Further studies are needed to in-
vestigate why there is inadequate dosing.
Understanding the prevalence, determinants and
spectrum of off-label medicine use can help developing
prevention strategies. Further studies are needed to in-
vestigate the reasons for off-label medicine use as it
might be due to lack of knowledge in paediatric pharma-
cotherapy or the absence of appropriate paediatric medi-
cation or based on empiricism.
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medication needs further research to identify whether this
is a particular German phenomenon or whether similar
patterns can be observed in other countries as well.
In addition to appropriate clinical trials for licensing of
paediatric medicines, education of health care profes-
sionals but also of parents and carers about the rational
and correct use of medicines is needed. This will ensure
the most appropriate use of medicines in the paediatric
population so that drug use can be based on well-
grounded information.
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